Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gonadotropin-releasing hormone antagonist |
| gptkbp:approvedBy |
gptkb:Europe
1999 |
| gptkbp:ATCCode |
H01CC02
|
| gptkbp:brand |
Antagon
|
| gptkbp:CASNumber |
124904-93-4
|
| gptkbp:chemicalClass |
peptide
|
| gptkbp:contraindication |
pregnancy
hypersensitivity to ganirelix |
| gptkbp:eliminationHalfLife |
13-16 hours
|
| gptkbp:hasMolecularFormula |
C81H112ClN17O16
|
| https://www.w3.org/2000/01/rdf-schema#label |
ganirelix acetate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
blocks GnRH receptors
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:proteinBinding |
78%
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
abdominal pain headache injection site reactions |
| gptkbp:usedFor |
in vitro fertilization
prevention of premature luteinizing hormone surges |
| gptkbp:bfsParent |
gptkb:Ganirelix
gptkb:Orgalutran |
| gptkbp:bfsLayer |
6
|